RA Capital Management, an investment company, led a $27m Series B round in Vaxess, a life sciences company developing a sustained-release vaccine patch, with participation from The Engine, Mission BioCapital, and Global Health Investment Corporation. The company intends to use the funds to support its recently-launched phase 1 trial for the H1 influenza vaccine delivered by VX-103.